KRRO
Korro Bio, Inc.
$12.25
-0.03
(-0.24%)
Mkt Cap
121.93M
Volume
169,635
52W Range
5.204-55.89
Sector
Healthcare
Beta
2.11
EPS (TTM)
-11.68
P/E Ratio
-0.64
Revenue (TTM)
3.84M
Rev Growth (5Y)
-29.6%
EPS Growth (5Y)
N/A
Company Description
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.39M | 2.27M | 0 | 0 | 14.07M | 36.98M | 28.95M | 0 | 0 |
| Net Income | (117.26M) | (83.58M) | (81.17M) | (58.03M) | (84.69M) | (26.51M) | (18.75M) | (19.17M) | (20.24M) |
| EPS | -12.48 | -9.37 | -53.09 | -227.58 | -4.94 | -41.10 | -30.39 | -30.57 | -32.27 |
| Free Cash Flow | (79.08M) | (77.98M) | (75.12M) | (58.86M) | (36.54M) | (51.86M) | 33.15M | (17.46M) | (16.48M) |
| FCF / Share | -8.42 | -8.74 | -49.13 | -230.81 | -8.22 | -80.39 | 53.74 | -27.84 | -26.28 |
| Operating CF | (78.56M) | (60.07M) | (67.28M) | (53.65M) | (32.09M) | (45.19M) | 34.22M | (17.02M) | (14.61M) |
| Total Assets | 113.51M | 226.24M | 221.66M | 73.74M | 185.36M | 264.72M | 223.22M | 44.55M | 19.79M |
| Total Debt | 43.49M | 44.77M | 33.21M | 166.99M | 45.60M | 45.99M | 0 | 84.94M | 46.69M |
| Cash & Equiv | 21.82M | 55.64M | 166.15M | 36.94M | 79.64M | 220.34M | 200.16M | 42.19M | 17.94M |
| Book Value | 51.44M | 160.41M | 169.91M | (99.03M) | 130.82M | 192.49M | 167.36M | (48.28M) | (29.64M) |
| Return on Equity | -2.28 | -0.52 | -0.48 | N/A | -0.65 | -0.14 | -0.11 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1.29M | 1.09M | 1.46M | 2.55M | 2.27M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.62M) | (50.04M) | (18.06M) | (25.77M) | (23.39M) | (21.20M) | (21.00M) | (21.83M) | (19.56M) | (25.43M) | (18.49M) | (17.65M) |
| EPS | -1.69 | -5.33 | -1.92 | -2.74 | -2.49 | -2.26 | -2.26 | -2.43 | -2.44 | -4.89 | -2.03 | -1.94 |
| Free Cash Flow | (16.09M) | (17.79M) | (17.35M) | (19.37M) | (24.57M) | (8.95M) | (20.97M) | (20.55M) | (27.50M) | (47.66M) | (12.02M) | (19.14M) |
| FCF / Share | -1.39 | -1.89 | -1.85 | -2.06 | -2.62 | -1.00 | -2.25 | -2.29 | -3.43 | -5.95 | -2.10 | -3.44 |
| Operating CF | (16.07M) | (17.70M) | (17.18M) | (19.23M) | (24.45M) | (7.50M) | (16.09M) | (14.59M) | (21.89M) | (39.92M) | (11.77M) | (14.71M) |
| Total Assets | 183.62M | 113.51M | 161.55M | 180.43M | 202.21M | 226.24M | 243.54M | 249.59M | 197.99M | 221.66M | 95.83M | 109.34M |
| Total Debt | 42.88M | 43.49M | 44.67M | 44.63M | 45.19M | 44.77M | 41.78M | 38.46M | 35.92M | 33.21M | 31.22M | 29.00M |
| Cash & Equiv | 61.70M | 21.82M | 25.16M | 33.61M | 64.14M | 55.64M | 63.21M | 91.15M | 138.80M | 166.15M | 46.12M | 59.33M |
| Book Value | 119.63M | 51.44M | 99.03M | 115.10M | 138.96M | 160.41M | 179.63M | 198.08M | 151.36M | 169.91M | 56.06M | 73.92M |
| Return on Equity | -0.16 | -0.97 | -0.18 | -0.22 | -0.17 | -0.13 | -0.12 | -0.11 | -0.13 | -0.15 | -0.33 | -0.24 |
KRRO News
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro to Present at the 2026 Jefferies Global Healthcare Conference
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro to Participate in Upcoming Investor Conferences
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts